Home

Arba Asseris Kotedžas idogen spotlight pakartojimas Puiku Vadovas

Trading Direkt analyserar bolagen på Spotlight 2018-10-18: Plejd & Idogen -  YouTube
Trading Direkt analyserar bolagen på Spotlight 2018-10-18: Plejd & Idogen - YouTube

biotech | pharma | diagnostics | devices
biotech | pharma | diagnostics | devices

niklas wallett - Idogen
niklas wallett - Idogen

PRESS RELEASE IDOGEN AB
PRESS RELEASE IDOGEN AB

Idogen will be listed on Nasdaq First North Growth Market on June 4, 2020
Idogen will be listed on Nasdaq First North Growth Market on June 4, 2020

Idogen files patent application for new tolerogenic cell therapy
Idogen files patent application for new tolerogenic cell therapy

Nyemission: Idogen förbereder för fas I/IIa-studie Idogen är ett svenskt  bioteknikbolag baserat i Lund. Bolaget utvecklar tolerogena cellterapier  som gör det möjligt att undvika en oönskad aktivering av kroppens  immunsystem. Cellterapin baseras
Nyemission: Idogen förbereder för fas I/IIa-studie Idogen är ett svenskt bioteknikbolag baserat i Lund. Bolaget utvecklar tolerogena cellterapier som gör det möjligt att undvika en oönskad aktivering av kroppens immunsystem. Cellterapin baseras

Idogen AB | Aktiespararna
Idogen AB | Aktiespararna

Noteringar i veckan
Noteringar i veckan

Iodogen | C16H10Cl4N4O2 | ChemSpider
Iodogen | C16H10Cl4N4O2 | ChemSpider

Idogen AB (publ)
Idogen AB (publ)

Investors Home
Investors Home

Idogen presentation - Idogen
Idogen presentation - Idogen

Idogen AB | Aktiespararna
Idogen AB | Aktiespararna

Idogen's Historical Milestones - Idogen
Idogen's Historical Milestones - Idogen

Idogen - Crunchbase Company Profile & Funding
Idogen - Crunchbase Company Profile & Funding

Board and Advisors | Ambulero
Board and Advisors | Ambulero

Redeye-intervju med Idogens VD om emissionsutfallet och rekryteringen av ny  CMO - IPO.se
Redeye-intervju med Idogens VD om emissionsutfallet och rekryteringen av ny CMO - IPO.se

biotech | pharma | diagnostics | devices
biotech | pharma | diagnostics | devices

Q3 ENG - Idogen
Q3 ENG - Idogen

Idogen Year end report 3 - Idogen
Idogen Year end report 3 - Idogen

Idogen's cell technology successfully advanced to large-scale production
Idogen's cell technology successfully advanced to large-scale production

Idogen - Engineering Immune Tolerance
Idogen - Engineering Immune Tolerance

Idogen AB (publ) Org nr
Idogen AB (publ) Org nr

Stories: EIC-funded company Idogen starts trading on Nasdaq First North  Growth Market | EIC Community
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community

Stories: EIC-funded company Idogen starts trading on Nasdaq First North  Growth Market | EIC Community
Stories: EIC-funded company Idogen starts trading on Nasdaq First North Growth Market | EIC Community